AVPR2 and autosomal dominant polycystic kidney disease: Recent clinical trials showed promising treatment potential of the vasopressin V2 receptor antagonist tolvaptan in ADPKD, as indicated by the slowed decline in kidney function and occurrence of advanced stages of chronic kidney disease (Torres et al., 2012, 2017).